#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	1618	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2509	130.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1379	1379	C	184	C	118	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2734	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3514	151.6	0	.	n	.	0	A20C	SNP	20	20	A	293	293	C	46	C	39	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2734	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3514	151.6	0	.	n	.	0	T695C	SNP	695	695	T	968	968	C	213	C	129	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2734	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3514	151.6	0	.	n	.	0	A1638G	SNP	1638	1638	A	1911	1911	G	119	G	86	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2734	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3514	151.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2244	2244	C	161	C	101	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2734	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3514	151.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2318	2318	A	155	A	101	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2734	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3514	151.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2870	2870	C	147	C	100	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	118	folP	855	855	100.0	folP.l6.c4.ctg.1	1416	17.4	1	SNP	p	R229S	1	.	.	685	687	AGC	1000	1002	AGC	21;21;23	A;G;C	14;15;16	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	280	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3101	18.2	1	SNP	p	S91F	1	.	.	271	273	TTC	350	352	TTC	20;20;20	T;T;C	11;11;10	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	280	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3101	18.2	1	SNP	p	G95N	0	.	.	283	285	GGC	362	364	GGC	20;20;20	G;G;C	11;11;10	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	280	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3101	18.2	1	SNP	p	D95G	1	.	.	283	285	GGC	362	364	GGC	20;20;20	G;G;C	11;11;10	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	90	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	987	17.8	0	.	p	.	0	F184L	NONSYN	550	552	TTC	702	704	TTG	17;17;17	T;T;G	12;12;11	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	90	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	987	17.8	1	SNP	p	G45D	0	.	.	133	135	GGC	285	287	GGC	25;25;25	G;G;C	17;17;17	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	58	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	590	15.8	0	.	n	.	0	A197.	DEL	197	197	A	205	205	A	29	A	19	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	280	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2837	20.5	1	SNP	p	D86N	0	.	.	256	258	GAC	578	580	GAC	22;22;23	G;A;C	16;14;16	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	280	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2837	20.5	1	SNP	p	R87I	0	.	.	259	261	CGT	581	583	CGT	23;23;22	C;G;T	15;13;13	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	280	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2837	20.5	1	SNP	p	R87W	0	.	.	259	261	CGT	581	583	CGT	23;23;22	C;G;T	15;13;13	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	280	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2837	20.5	1	SNP	p	S87R	1	.	.	259	261	CGT	581	583	CGT	23;23;22	C;G;T	15;13;13	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	280	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2837	20.5	1	SNP	p	S88P	0	.	.	262	264	TCC	584	586	TCC	22;22;22	T;C;C	14;14;14	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	250	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3220	15.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1776	1778	GGC	13;14;15	G;G;C	11;11;10	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	246	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2266	21.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1290	1292	GCA	34;34;34	G;C;A	21;20;20	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	246	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2266	21.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1293	1295	ATC	34;34;34	A;T;C	21;20;19	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	246	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2266	21.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1305	1307	GTG	34;34;34	G;T;G	21;19;20	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	246	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2266	21.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1305	1307	GTG	34;34;34	G;T;G	21;19;20	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	246	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2266	21.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1809	1811	ACC	9;9;9	A;C;C	5;5;6	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	246	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2266	21.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1863	1865	GCG	6;6;6	G;C;G	6;4;6	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	246	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2266	21.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1863	1865	GCG	6;6;6	G;C;G	6;4;6	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	246	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2266	21.6	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1986	1988	AGC	18;18;19	A;G;C	12;10;10	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	246	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2266	21.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1995	1997	GGC	19;19;19	G;G;C	12;13;9	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	246	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2266	21.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2013	2015	CCG	19;19;19	C;C;G	11;9;11	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	504	ponA	2397	2397	99.92	ponA.l15.c4.ctg.1	2740	33.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	154	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1955	16.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	532	532	C	14	C	7	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1744	19.3	0	.	p	.	0	N38E	NONSYN	112	114	AAT	416	418	GAA	18;16;16	G;A;A	12;11;11	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1744	19.3	0	.	p	.	0	P175S	NONSYN	523	525	CCA	827	829	TCA	24;24;24	T;C;A	15;14;15	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1744	19.3	0	.	p	.	0	A218V	NONSYN	652	654	GCC	956	958	GTC	17;18;18	G;T;C	11;13;13	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1744	19.3	0	.	p	.	0	F222S	NONSYN	664	666	TTT	968	970	TCT	17;17;17	T;C;T	11;12;10	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1744	19.3	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1286	1288	GCA	30;30;30	G;C;A	20;19;20	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1744	19.3	1	SNP	p	G120K	1	.	.	358	360	AAG	662	664	AAG	19;19;19	A;A;G	12;13;13	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1744	19.3	1	SNP	p	D121N	0	.	.	361	363	GAC	665	667	GAC	19;19;19	G;A;C	13;12;13	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1744	19.3	1	SNP	p	A121D	1	.	.	361	363	GAC	665	667	GAC	19;19;19	G;A;C	13;12;13	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	734	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5102	28.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	22	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	836	5.3	1	SNP	p	V57M	1	.	.	169	171	ATG	373	375	ATG	10;10;10	A;T;G	7;7;7	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
